Indeed, among these patients with Lynch syndrome, 71.2% and 78.4% of germline pathogenic variants were detected in MLH1, MSH2, or EPCAM genes in MSI-H/I tumors, but in the lower-penetrance PMS2 or MSH6 genes in MSS tumors. This evidence concerns the gene MSH6 and Lynch syndrome.